Idogen’s investor events in October-November 2018

During October and November 2018, Idogen AB’s (“Idogen”) CEO Lars Hedbys will present the company at several investor events. New and future shareholders are warmly welcomed to the events. For more information, see below.

BioStock Life Science Summit in Lund, October 25

Time: Thursday October 25 2018, at 13:25-13:45

Location: Medicon Village, Lund

Organizer: BioStock, for more information and participation, please visit: summit.biostock.se 

Sedermeradagen in Stockholm, November 7

Time: Wednesday November 7 2018, time to be decided

Location: Waterfront Congress Center, Stockholm

Organizer: Sedermera Fondkommission, for more information and participation, please visit: sedermera.se 

Stora aktiedagen Göteborg, November 12

Time: Monday November 12 2018, at 15:40-16:10

Location: Svenska Mässan, Mässans Gata/Korsvägen, Göteborg 

Organizer: Aktiespararna, for more information and participation, please visit: aktiespararna.se

Aktiekvällen i Lund, November 15

Time: Thursday November 15 2018, at 18:00-18:30 

Location: Elite Hotel Ideon, Scheelevägen 27, Lund 

Organizer: Aktiespararna, for more information and participation, please visit: aktiespararna.se 

Stora aktiedagen Stockholm, November 26

Time: Monday November 26 2018, at 11:20-11:50 

Location: Sheraton Stockholm Hotel, Tegelbacken 6, Stockholm 

Organizer: Aktiespararna, for more information and participation, please visit: aktiespararna.se 

For additional information, please contact:

Lars Hedbys, CEO Idogen AB

Tel: +46 (0)46-275 63 30

E-mail: lars.hedbys@idogen.com

Idogen (Spotlight Stock Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body’s own cells or tissue. Idogen’s most advanced product candidate IDO 8 is designed for patients with severe haemophilia A who have developed anti-drug antibodies against their critical treatment with coagulation factor VIII (factor VIII). The company´s second project IDO T is developed to prevent kidney transplant rejection. In a third project, IDO AID, Idogen focuses on the treatment of autoimmune diseases. The treatment is based on the patient’s own cells and is expected to have a favorable safety profile and long-lasting effect. The fact that a short treatment has the potential to yield a long-lasting effect is another great advantage. For more information, visit https://www.idogen.com 

Attached file